Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease

Table 1 Patient characteristics

	n = 119
Age (yr), mean ± SD	56 ± 10.7
18-30, n (%)	2 (1.7)
31-50, n (%)	30 (25.2)
51-70, n (%)	79 (66.4)
> 70, n (%)	8 (6.7)
Sex (male), n (%)	79 (66.4)
Metabolic syndrome, n (%)	73 (61.3)
Increased waist circumference, n (%)	91 (76.5)
Hypertension, n (%)	63 (52.9)
Type 2 diabetes mellitus, n (%)	66 (55.5)
Increased Triglyceride levels, n (%)	61 (51.3)
Low HDL-cholesterol levels, n (%)	53 (44.5)
HOMA-IR, mean ± SD	7.5 ± 13.1
BMI (kg/m2), mean ± SD	32.5 ± 5.2
Obese, n (%)	74 (62.2)
Normal BMI, n (%)	6 (5)
Waist circumference (cm), mean ± SD	109.3 ± 14
Visceral fat, mean ± SD1	14.8 ± 5.3
Visceral fat ≥ 13, n (%)2	77 (63.6)
CAP (dB/m), mean ± SD	330.9 ± 50.4
Liver elastography (Kpa), mean ± SD	11.7 ± 8
Histological fibrosis stage, n (%)
F0-1	59 (49.6)
F2	18 (15.1)
F3	24 (20.2)
F4	18 (15.1)

¹Measured by bioimpendanciometry analysis.

²Upper threshold of normality provided by the manufacturer. HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; HDL-cholesterol: High-density lipoprotein cholesterol; CAP: Controlled attenuation parameter.